Effects of Aerobic Exercise on Cancer-Related Biomarkers, Functional Capacity, Cognitive Status and Quality of Life in Women With Breast Cancer
Launched by HASAN KALYONCU UNIVERSITY · Aug 2, 2024
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is exploring whether exercise can help women who have survived breast cancer feel better and function better. It compares three groups over 12 weeks: (1) moderate‑intensity aerobic exercise three times a week, (2) personalized physical activity counseling to help you stay active, and (3) no new exercise (usual daily activities). Researchers will look at quality of life, how far you can walk in six minutes (a measure of physical fitness), and thinking/cognitive function, plus several blood markers related to inflammation and metabolism. Assessments are planned at the start, at 6 weeks, and at 12 weeks.
To be eligible, you’d need to be a woman aged 18–65 with stage 2 breast cancer who finished primary treatment at least six months ago (not on hormone therapy), be able to read, and be willing to participate. Exclusions include metastasis, a history of lymphedema, certain health conditions, pregnancy, or certain medications. The study is based at Hasan Kalyoncu University in Ankara, Turkey and is currently enrolling about 69 participants. Results aren’t available yet, but the trial aims to show whether exercise or counseling can improve quality of life, physical ability, and possibly inflammatory and metabolic biomarkers in breast cancer survivors.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients aged between 18 and 65
- • Literate
- • Diagnosed with stage 2 breast cancer
- • Completed primary breast cancer treatment at least 6 months ago (excluding hormone therapy/aromatase inhibitors)
- • Provided cooperation
- • Female
- • Patients who are willing and willing to participate in the study
- Exclusion Criteria:
- • Those who are using psychotic, anxiolytic, antidepressant, analgesic and sleeping pills
- • Those with metastasis
- • Those with a history of lymphedema
- • Those with neurological disease
- • Those who are pregnant or breastfeeding
- • Uncontrolled hypertensive patients
- • Those who are incapable of verbal communication or physical movement
About Hasan Kalyoncu University
Hasan Kalyoncu University is a distinguished academic institution dedicated to advancing research and education in the health sciences. With a commitment to innovation and excellence, the university actively sponsors clinical trials aimed at enhancing medical knowledge and improving patient outcomes. By fostering collaboration among researchers, healthcare professionals, and industry partners, Hasan Kalyoncu University strives to contribute to the development of effective therapies and interventions, ultimately aiming to address pressing health challenges and promote public well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yeni̇mahalle, Ankara, Turkey
Patients applied
Trial Officials
Nahide Fidancıoğlu
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported